Who makes human single chain IL-12 mRNA-multiple dose?

human single chain IL-12 mRNA-multiple dose is developed by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

What development phase is human single chain IL-12 mRNA-multiple dose in?

human single chain IL-12 mRNA-multiple dose is in Phase 1.

Last reviewed 2026-05-14 · How we verify

human single chain IL-12 mRNA-multiple dose

Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	human single chain IL-12 mRNA-multiple dose
Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

human single chain IL-12 mRNA-multiple dose CI brief — competitive landscape report
human single chain IL-12 mRNA-multiple dose updates RSS · CI watch RSS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences portfolio CI